Comparative Pharmacology
Head-to-head clinical analysis: DAYPRO ALTA versus RUFEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DAYPRO ALTA versus RUFEN.
DAYPRO ALTA vs RUFEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oxaprozin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, decreasing prostaglandin synthesis.
Oxaprozin is administered orally. The usual adult dose is 1200 mg once daily. For osteoarthritis and rheumatoid arthritis, dosing can range from 600 to 1200 mg once daily. A starting dose of 600 mg once daily may be considered for patients with low body weight or milder disease.
400-800 mg orally three to four times daily; maximum 3200 mg/day.
None Documented
None Documented
50-65 hours (mean 57 hours); clinically significant accumulation occurs with multiple dosing, requiring dose adjustment in elderly and renal impairment.
Terminal elimination half-life is 2-4 hours; clinical context: short half-life requires frequent dosing for sustained analgesia.
Renal: 85% (60-90% as oxaprozin glucuronide and 5-10% as unchanged oxaprozin); Fecal: <5%; Biliary: negligible.
Primarily renal (approximately 90% as glucuronide conjugates and unchanged drug), with minor biliary/fecal elimination (<10%).
Category C
Category C
Nonsteroidal Anti-Inflammatory Drug (NSAID)
Nonsteroidal Anti-Inflammatory Drug (NSAID)